Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Jacksonville Journal-Courier on MSN2d
SamJam fundraiser back for one last goOne of the most popular music festivals in small-town Illinois is coming to an end after a 10-year run. SamJam’s Finale is ...
Videos of the race on social media have gone viral, including one posted this year from upstairs at Klondike Kate's showing a ...
Videos of the race on social media have gone viral, including one posted this year from upstairs at Klondike Kate's showing a bird's-eye view ... 2025 raises money for neurofibromatosis cure ...
The development of ocular signs of neurofibromatosis type 1 (NF1) is only significant in patients 7 years of age and younger.
On Monday, activist Idelisa Diasniurka Salcedo Verdecia voiced her concerns regarding the chemotherapy administered to young ...
Positive updates continue to emerge from Nicklaus Children's Hospital in Miami, where young Damir Ortiz, a Cuban child in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback